TEVA News & Events

Veeva Systems (VEEV) announced that Teva Pharmaceuticals (TEVA) has committed to Veeva Vault CRM globally. "We are excited to expand our strategic partnership with Veeva by moving to Vault CRM," said Lavanya Narasimhamurthy, global vice president of IT at Teva. "We share a deep commitment to customer success, and Vault CRM will provide Teva the technical foundation to drive commercial execution."

Teva Pharmaceuticals International announced that the European Medicines Agency has accepted the Marketing Authorization Application for olanzapine long-acting injectable for the treatment of schizophrenia in adults. TEV-'749 aims to address treatment adherence in real-world settings and contribute to long-term disease management in people living with schizophrenia. TEV-'749 is not approved by any regulatory authority worldwide at this time. The submission to the EMA is supported by an extensive clinical development program, including the Phase 3 SOLARIS study. Across clinical development, TEV-'749 demonstrated efficacy, a systemic safety profile, and exposure consistent with oral olanzapine. TEV-'749 utilizes SteadyTeq, a copolymer technology proprietary to Medincell that provides a controlled, steady, prolonged release of olanzapine.